哮喘联盟

   摘要 
   一项最新文献检索研究评估了干粉吸入速效β2受体激动剂治疗中-重度急性哮喘的疗效。搜索1985年到2012年12月的数据库，共23项关于急性哮喘治疗的随机双盲或开放性临床试验纳入研究。这些试验在可控的医院环境中，比较了干粉吸入器与定向吸入气雾器、雾化器治疗急性哮喘的效果。本综述发现使用干粉吸入器吸入β2受体激动剂型支气管扩张药（福莫特罗，沙丁胺醇，特布他林和布地奈德/福莫特罗）能有效治疗严重哮喘恶化和急性哮喘发作，疗效与使用定向吸入气雾器（使用/不使用垫片）、雾化治疗这些已确定的治疗方案同等。这些结果确保患者在哮喘发作时可依赖于干粉吸入器，正如其他的吸入装置一样。
 

（刘国梁 审校）
Ther Deliv. 2014 Jan;5(1):69-81. doi: 10.4155/tde.13.132.

 

Dry-powder inhalers in acute asthma.
 

Selroos O.
 

Abstract
An updated literature search was performed to evaluate the efficacy of rapid-acting β2-agonists delivered via dry powder inhalers in the treatment of moderate-to-severe acute asthma. Databases were searched from 1985 up to December 2012. A total of 23 randomized, double-blind or open clinical studies in acute asthma comparing the efficacy of a dry powder inhaler with a pressurized metered-dose inhaler or a nebulizer, and performed under controlled hospital conditions, were identified. This review found that administration of β2-agonist bronchodilators via dry powder inhalers (formoterol, salbutamol, terbutaline and budesonide/formoterol) was effective during severe asthma worsening and acute asthma attacks, and was as effective as established therapies with a pressurized metered-dose inhaler with or without a spacer, or nebulization. These results ensure that patients can rely upon dry powder inhalers equally well as other inhaler devices during episodes of asthma worsening.
 

Ther Deliv. 2014 Jan;5(1):69-81. doi: 10.4155/tde.13.132.